Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;126(1):150-160.
doi: 10.1002/jso.26929.

PD-L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy

Héber S C Ribeiro  1 , Jacqueline N Menezes  1 , Wilson L da Costa Jr  1   2 , Victor Hugo F de Jesus  3 , Alessandro L Diniz  1 , André L Godoy  1 , Igor Correia de Farias  1 , Silvio M Torres  1 , Tatiane Neotti  4 , Celso A L Mello  3 , Maria Dirlei F S Begnami  5 , Emmanuel Dias-Neto  6 , Rachel P Riechelmann  3 , Felipe José Fernandez Coimbra  1
Affiliations

PD-L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy

Héber S C Ribeiro et al. J Surg Oncol. 2022 Jul.

Abstract

Background and objectives: The incidence, predictive, and prognostic impact of programmed cell death (PD-L1) expression in gastric (GC) and gastroesophageal junction tumors (GEJC) treated with perioperative chemotherapy is poorly understood. We aimed to assess PD-L1 expression by immunohistochemistry (IHC) in both pre and posttreatment specimens evaluating its impact on pathological response and survival outcomes.

Methods: Retrospective cohort of patients with GC and GEJ tumors treated in a single western cancer center between 2007 and 2017. PD-L1 expression was assessed by IHC before and after neoadjuvant chemotherapy, in surgical samples, and reported as combined positive score (CPS). CPS > 1% was tested for its association with pathological response and overall survival (OS).

Results: We were able to assess PD-L1 expression in at least one tissue sample from 155 subjects. PD-L1 positivity rate was 20%. In 74 paired samples, a 21% discordance between PD-L1 expression in biopsy sample and surgical specimen was observed. With a median follow-up period of 60.3 months, 5-years disease-free survival was 60.5% with a median OS not reached. PD-L1 expression was neither associated with pathological response or survival outcomes.

Conclusions: PD-L1 expression in the setting of locally advanced GC tumors was relatively low and can vary considering the tissue sample analyzed. This expression had no association with survival or pathological response in this population.

Keywords: PD-L1; gastric cancer; neoadjuvant treatment; prognosis.

PubMed Disclaimer

References

REFERENCES

    1. GLOBOCAN. Cancer fact sheets, stomach. 2020.
    1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953.
    1. Lee HK, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg. 2001;88(10):1408-1412.
    1. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013.
    1. Janjigian YY, Shitara K, Moehler M, et al. Nivolumab plus chemotherapy versus chemotherapy as first line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27-40.